Geode Capital Management
HCWB icon

Geode Capital Management’s HCW Biologics HCWB Stock Holding History

Geode Capital Management’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,981
Closed -$12.9K – 4506
2026
Q1 		$12.9K Buy
5,981
+3,641
+156% +$18.8K ﹤0.01% 4478
2025
Q4 		$13.6K Buy
2,340
+506
+28% +$8.6K ﹤0.01% 4414
2025
Q3 		$40.7K Buy
+1,834
New +$47.9K ﹤0.01% 4336
2025
Q2 		– Sell
-987
Closed -$66.9K – 4476
2025
Q1 		$66.9K Buy
987
+229
+30% +$20.1K ﹤0.01% 4137
2024
Q4 		$81.2K Sell
758
-6
-0.8% -$700 ﹤0.01% 4148
2024
Q3 		$98.9K Buy
764
+54
+8% +$7.36K ﹤0.01% 4104
2024
Q2 		$110K Sell
710
-16
-2% -$4.73K ﹤0.01% 4115
2024
Q1 		$291K Buy
726
+166
+30% +$53.1K ﹤0.01% 3805
2023
Q4 		$165K Buy
560
+8
+1% +$2.73K ﹤0.01% 4005
2023
Q3 		$253K Buy
552
+6
+1% +$2.97K ﹤0.01% 3884
2023
Q2 		$284K Hold
546
– – ﹤0.01% 3888
2023
Q1 		$181K Hold
546
– – ﹤0.01% 4099
2022
Q4 		$251K Sell
546
-1
-0.2% -$517 ﹤0.01% 3970
2022
Q3 		$300K Buy
547
+316
+137% +$181K ﹤0.01% 3985
2022
Q2 		$121K Buy
231
+9
+4% +$5.05K ﹤0.01% 4505
2022
Q1 		$145K Buy
222
+45
+25% +$24K ﹤0.01% 4517
2021
Q4 		$98K Buy
177
+88
+99% +$59.8K ﹤0.01% 4740
2021
Q3 		$68K Buy
+89
New +$93.6K ﹤0.01% 4743

Other funds holding HCWB

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's HCWB Position: Q2 2026 in Review

Geode Capital Management sold out of HCW Biologics (HCWB) in Q2 2026, closing a stake of 5,981 shares — an estimated $12.9K sold.

Geode Capital Management first reported a position in HCWB in Q3 2021 and held it in 18 quarters. The position peaked at $300K in Q3 2022. 7 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

  • Geode Capital Management reported no remaining HCW Biologics position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 5,981 HCW Biologics shares in Q2 2026, an estimated $12.9K.
  • Geode Capital Management first reported a position in HCW Biologics in Q3 2021 and held it in 18 quarters.
  • Geode Capital Management's HCW Biologics position peaked at $300K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.